None listed
Conditions
Brief summary
PEOPLE/SHOP is a prospective, longitudinal, multicentre cohort study conducted at 4 sites in New Zealand and 5 sites in Singapore. The aims are to: 1. To determine proportion of patients with heart failure who have Heart Failure-Preserved Ejection Fraction (HF-PEF) according to newly proposed European Society of Cardiology criteria. 2. To determine clinical outcome for patients with HF-PEF with patients with heart failure with low ejection fraction (HF-lowEF). 3. To determine clinical, echocardiographic and neurohormonal characteristics and predictors of outcome in HF-PEF compared to HF-lowEF. Subjects will be those patients with heart failure who are either admitted to hospital or seen in an out-patient clinic with a primary diagnosis of heart failure. Clinical characteristics, echocardiographic and neurohormonal status will be documented at the time of enrolment. Follow up visits will be undertaken at 6 weeks and 6 months, when clinical, quality of life, echocardiographic (6 months only) and neurohormonal status will be determined. Clinical events will be followed for 2 years.
Interventions
Condition observed: Heart Failure
Baseline visit, then follow up visits will be undertaken at 6 weeks and 6 months - clinical, quality of life, echocardiography (6 months only) and neurohormonal status will be determined. Clinical events will be followed for 2 years.
This is an observational study and does not involve interventions.
Sponsors
University of Auckland
Eligibility
Sex/Gender
All
Age
0 to No maximum
Healthy volunteers
No
Inclusion criteria
Patients who either: a) Present to hospital with a primary diagnosis of heart failure, or b) Attend a hospital clinic for management of HF within 6 months of diagnosis
Exclusion criteria
Patients will be excluded from this study if: a) HF is primarily due to valve disease b) if the primary diagnosis is an acute coronary syndrome which has resulted in a transient episode of acute pulmonary oedema. (Note: patients with a troponin rise noted during the index admission, but in whom the main presentation is considered clinically to be HF will be included). c) the patient has end stage renal failure estimated glomerular filtration rate (eGFR)<15ml/min/m2 or is receiving or planned to receive renal replacement therapy d) constrictive pericarditis e) other life threatening comorbidity with a life expectancy of <1 year f) inability to provide informed consent g) inability to comply with study protocol requirements Patients who are unable to attend for follow-up will still be considered for the study even if they are not able to undertake the post discharge study visits.
Outcome results
None listed